Related Experiment Video
Updated: Dec 22, 2025

A Semi-Automated and Reproducible Biological-Based Method to Quantify Calcium Deposition In Vitro
Published on: June 2, 2022
Calciprotein Particles and Serum Calcification Propensity: Hallmarks of Vascular Calcifications in Patients with
Ciprian N Silaghi1, Tamás Ilyés1, Adriana J Van Ballegooijen2
1Department of Molecular Sciences, University of Medicine and Pharmacy "Iuliu Hațieganu", 400012 Cluj-Napoca, Romania.
Insights
Serum calciprotein particles (CPPs) and the T50 test indicate calcification tendency. This review explores their role in vascular calcification (VC) and chronic diseases, especially in kidney disease patients.
Area of Science:
- Biochemistry
- Nephrology
- Cardiology
Background:
- Cardiovascular complications and vascular calcification (VC) are major mortality causes.
- Chronic kidney disease (CKD) patients exhibit increased VC and mortality risk.
- Serum calciprotein particles (CPPs) drive VC initiation and progression.
Purpose of the Study:
- To comprehensively review factors influencing serum CPP levels and T50 test results.
- To explore the impact of CPPs and calcification propensity on chronic disease outcomes.
- To discuss potential clinical applications of the T50 test in VC assessment and management, particularly in CKD.
Main Methods:
- Comprehensive literature search on serum CPPs, T50 test, and VC.
- Analysis of factors affecting CPP levels and T50.
- Exploration of the link between calcification propensity and disease outcomes.
Main Results:
- Serum CPPs and T50 reflect the propensity for serum calcification.
- Calcification propensity is linked to cardiovascular and all-cause mortality.
- The T50 test shows promise for assessing VC in CKD patients.
Conclusions:
- Understanding CPPs and T50 is crucial for managing VC.
- The T50 test may offer new clinical avenues for VC assessment and treatment.
- Further research could lead to novel strategies for controlling VC and improving patient outcomes.
Abstract:
Cardiovascular complications are one of the leading causes of mortality worldwide and are strongly associated with atherosclerosis and vascular calcification (VC). Patients with chronic kidney disease (CKD) have a higher prevalence of VC as renal function declines, which will result in increased mortality. Serum calciprotein particles (CPPs) are colloidal nanoparticles that have a prominent role in the initiation and progression of VC. The T50 test is a novel test that measures the conversion of primary to secondary calciprotein particles indicating the tendency of serum to calcify. Therefore, we accomplished a comprehensive review as the first integrated approach to clarify fundamental aspects that influence serum CPP levels and T50, and to explore the effects of CPP and calcification propensity on various chronic disease outcomes. In addition, new topics were raised regarding possible clinical uses of T50 in the assessment of VC, particularly in patients with CKD, including possible opportunities in VC management. The relationships between serum calcification propensity and cardiovascular and all-cause mortality were also addressed. The review is the outcome of a comprehensive search on available literature and could open new directions to control VC.
Related Concept Videos
Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease I: Introduction
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease IV: Nursing Management
Skeleton and Calcium Homeostasis

